Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma

International Journal of Oral and Maxillofacial Surgery

Volumn 36, Issue 3, 2007, Pages 230-234

  Zhong, L P ^a   Zhu, H G ^a   Zhang, C P ^a   Chen, W T ^a   Zhang, Z Y ^a  

^a Chongqing Ninth People's Hospital   (China)

Author keywords

Cyfra 21 1; enzyme linked immunoadsorbent assay; oral cavity; serum; squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KERATINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33846667831     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2006.06.016     Document Type: Article

References (26)

1. Banal A., Hacene K., Berthelot-Ruff E., Mahe E., Fontana X., and Pichon M.F. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol 22 (2001) 27-35
2. Buntzel J., Hornig A., Glatzel M., Micke O., Bruns F., Schafer U., and Frohlich D. Tumour markers and lymphatic metastasis in head and neck cancer patients. Anticancer Res 25 (2005) 1539-1542
3. Ceruse P., Rabilloud M., Charrie A., Dubreuil C., and Disant F. Study of cyfra 21-1, a tumour marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 114 (2005) 768-776
4. De Vicente J.C., Recio O.R., Pendas S.L., Pendas S.L., and Lopez-Arranz J.S. Oral squamous cell carcinoma of the mandibular region: a survival study. Head Neck 23 (2001) 536-543
5. Deng Y.F., Chen P., Lin Y.Z., Le J.Z., Wu X.L., Yu M.Q., Zhuang P.Y., and Gao M.H. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117 (2003) 190-194
6. Doweck I., Barak M., Greenberg E., Uri N., Kellner J., Lurie M., and Gruener N. Cyfra 21-1. A new potential tumour marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121 (1995) 177-181
7. Doweck I., Barak M., Uri N., and Greenberg E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83 (2000) 1696-1701
8. Franca A.V., Elias Junior J., Lima B.L., Martinelli A.L., and Carrilho F.J. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 37 (2004) 1689-1705
9. Gadducci A., Cosio S., Carpi A., Nicolini A., and Genazzani A.R. Serum tumour markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58 (2004) 24-38
10. Goldstein M.J., and Mitchell E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23 (2005) 338-351
11. Goumas P.D., Mastronikolis N.S., Mastorakou A.N., Vassilakos P.J., and Nikiforidis G.C. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 59 (1997) 106-114
12. Hoffmann J., Munz A., Krimmel M., and Alfter G. Intraoperative and postoperative kinetics of serum tumour markers in patients with oral carcinoma. J Oral Maxillofac Surg 56 (1998) 1390-1393
13. Hoffmann-Fazel A., Hoffmann M., Gottschlich S., Maass J.D., Rudert H., and Maune S. Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma. Anticancer Res 23 (2003) 917-920
14. Inal E., Lacin M., Asal K., Ceylan A., Koybasioglu A., Ileri F., and Uslu S.S. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Kulak Burun Bogaz Ihtis Derg 12 (2004) 23-30
15. Kurokawa H., Yamashita Y., Tokudome S., and Kajiyama M. Combination assay for tumour markers in oral squamous cell carcinoma. J Oral Maxillofac Surg 55 (1997) 964-966
16. Kuropkat C., Lippert B.M., and Werner J.A. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology 63 (2002) 280-285
17. Lai R.S., Hsu H.K., Lu J.Y., Ger L.P., and Lai N.S. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumour marker in non-small cell lung cancer. Chest 109 (1996) 995-1000
18. Nagler R.M., Barak M., Peled M., Ben-Aryeh H., Filatov M., and Laufer D. Early diagnosis and treatment monitoring roles of tumour markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 85 (1999) 1018-1025
19. Neville B.W., and Day T.A. Oral cancer and precancerous lesions. CA Cancer J Clin 52 (2002) 195-215
20. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J Clin 55 (2005) 74-108
21. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., and Michel F.B. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53 (1993) 61-66
22. Sanchez-Carbayo M., Espasa A., Chinchilla V., Herrero E., Megias J., Mira A., and Soria F. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45 (1999) 1944-1953
23. Sobin L.H., and Wittekind C.h. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 5th Edition (1997), Wiley-Liss, Inc, New York 20-24
24. Wollenberg B., Jan V., Schmit U.M., Hofmann K., Stieber P., and Fateh-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 16 (1996) 3117-3124
25. Yamamoto K., Oka M., Hayashi H., Tangoku A., Gondo T., and Suzuki T. CYFER 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79 (1997) 1647-1655
26. Yen T.C., Lin W.Y., Kao C.H., Cheng K.Y., and Wang S.J. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 23 (1998) 82-86